NeuroSense Therapeutics L...

NASDAQ: NRSN · Real-Time Price · USD
1.20
0.03 (2.56%)
At close: Aug 15, 2025, 3:05 PM

NeuroSense Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
22K 97K 89K n/a
Gross Profit
-22K -97K -89K -3K
Operating Income
-9.9M -12.05M -13.55M -5.59M
Interest Income
2K 178K 91K n/a
Pretax Income
-10.21M -11.28M -12.34M -4.04M
Net Income
-10.21M -10.11M -10.49M -2.5M
Selling & General & Admin
4.18M 4.78M 7.14M 2.5M
Research & Development
5.7M 7.27M 6.42M 3.08M
Other Expenses
n/a n/a n/a n/a
Operating Expenses
9.88M 12.05M 13.55M 5.59M
Interest Expense
311K 550K 15K 1.15M
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
9.9M 12.05M 13.55M 2.98M
Income Tax Expense
n/a n/a -1.14M -1.55M
Shares Outstanding (Basic)
18.6M 13.64M 11.51M 10.86M
Shares Outstanding (Diluted)
18.6M 13.64M 11.51M 10.86M
EPS (Basic)
-0.55 -0.83 -0.97 -0.23
EPS (Diluted)
-0.55 -0.83 -0.97 -0.23
EBITDA
-9.88M -9.64M -13.38M -2.88M
EBIT
-9.9M -9.66M -12.32M -2.89M
Depreciation & Amortization
22K 97K 89K 3K